Identification of a neutralization epitope in the VP1 capsid protein of SV40

Virology

Volumn 381, Issue 1, 2008, Pages 116-122

  Murata, Haruhiko ^a   Teferedegne, Belete ^a   Sheng, Li ^a   Lewis Jr , Andrew M ^a   Peden, Keith ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Epitope; Monoclonal antibody; Neutralization; SV40; VP1

Indexed keywords

NEUTRALIZING ANTIBODY; PROTEIN VP1;

ARTICLE; CONTROLLED STUDY; CROSS REACTION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; PRIORITY JOURNAL; PROTEIN CONFORMATION; SIMIAN VIRUS 40; VIRUS IDENTIFICATION; VIRUS NEUTRALIZATION;

ANTIBODIES, VIRAL; CAPSID PROTEINS; CELL LINE; EPITOPE MAPPING; EPITOPES; HUMANS; MUTATION; NEUTRALIZATION TESTS; PHENOTYPE; SIMIAN VIRUS 40;

BK POLYOMAVIRUS; MIRIDAE; POLYOMAVIRUS; PRIMATES;

EID: 54049110945     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.07.032     Document Type: Article

References (27)

1. Allander T., Andreasson K., Gupta S., Bjerkner A., Bogdanovic G., Persson M.A., Dalianis T., Ramqvist T., and Andersson B. Identification of a third human polyomavirus. J. Virol. 81 8 (2007) 4130-4136
2. Babé L.M., Brew K., Matsuura S.E., and Scott W.A. Epitopes on the major capsid protein of simian virus 40. J. Biol. Chem. 264 5 (1989) 2665-2671
3. Carter J.J., Madeleine M.M., Wipf G.C., Garcea R.L., Pipkin P.A., Minor P.D., and Galloway D.A. Lack of serologic evidence for prevalent simian virus 40 infection in humans. J. Natl. Cancer Inst. 95 20 (2003) 1522-1530
4. Chen X.S., Stehle T., and Harrison S.C. Interaction of polyomavirus internal protein VP2 with the major capsid protein VP1 and implications for participation of VP2 in viral entry. EMBO. J. 17 12 (1998) 3233-3240
5. Cutrone R., Lednicky J., Dunn G., Rizzo P., Bocchetta M., Chumakov K., Minor P., and Carbone M. Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961. Cancer Res. 65 22 (2005) 10273-10279
6. Feng H., Shuda M., Chang Y., and Moore P.S. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319 5866 (2008) 1096-1100
7. Gaynor A.M., Nissen M.D., Whiley D.M., Mackay I.M., Lambert S.B., Wu G., Brennan D.C., Storch G.A., Sloots T.P., and Wang D. Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS. Pathog. 3 5 (2007) e64
8. Hirsch H.H., and Steiger J. Polyomavirus BK. Lancet. Infect. Dis. 3 10 (2003) 611-623
9. Hirt B. Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 26 2 (1967) 365-369
10. Jin L., Gibson P.E., Knowles W.A., and Clewley J.P. BK virus antigenic variants: sequence analysis within the capsid VP1 epitope. J. Med. Virol. 39 1 (1993) 50-56
11. Kimchi-Sarfaty C., and Gottesman M.M. SV40 pseudovirions as highly efficient vectors for gene transfer and their potential application in cancer therapy. Curr. Pharm. Biotechnol. 5 5 (2004) 451-458
12. Knowles W.A., Gibson P.E., and Gardner S.D. Serological typing scheme for BK-like isolates of human polyomavirus. J. Med. Virol. 28 2 (1989) 118-123
13. Liddington R.C., Yan Y., Moulai J., Sahli R., Benjamin T.L., and Harrison S.C. Structure of simian virus 40 at 3.8-A resolution. Nature 354 6351 (1991) 278-284
14. Minor P., Pipkin P., Jarzebek Z., and Knowles W. Studies of neutralising antibodies to SV40 in human sera. J. Med. Virol. 70 3 (2003) 490-495
15. Murata H., Peden K., and Lewis Jr. A.M. Identification of a mutation in the SV40 capsid protein VP1 that influences plaque morphology, vacuolization, and receptor usage. Virology 370 2 (2008) 343-351
16. Peden K.W.C., Pipas J.M., Pearson-White S., and Nathans D. Isolation of mutants of an animal virus in bacteria. Science 209 4463 (1980) 1392-1396
17. Poulin D.L., and DeCaprio J.A. Is there a role for SV40 in human cancer?. J. Clin. Oncol. 24 26 (2006) 4356-4365
18. Roberts D.M., Nanda A., Havenga M.J., Abbink P., Lynch D.M., Ewald B.A., Liu J., Thorner A.R., Swanson P.E., Gorgone D.A., Lifton M.A., Lemckert A.A., Holterman L., Chen B., Dilraj A., Carville A., Mansfield K.G., Goudsmit J., and Barouch D.H. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441 7090 (2006) 239-243
19. Seth P., Diaz F., and Major E.O. Advances in the biology of JC virus and induction of progressive multifocal leukoencephalopathy. J. Neurovirol. 9 2 (2003) 236-246
20. Shah K.V., Galloway D.A., Knowles W.A., and Viscidi R.P. Simian virus 40 (SV40) and human cancer: a review of the serological data. Rev. Med. Virol. 14 4 (2004) 231-239
21. Stehle T., Gamblin S.J., Yan Y., and Harrison S.C. The structure of simian virus 40 refined at 3.1 A resolution. Structure 4 2 (1996) 165-182
22. In: Stratton K., Alamario D.A., and McCormick M.C. (Eds). Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer (2003), The National Academies Press, Washington, DC
23. Strayer D.S., Cordelier P., Kondo R., Liu B., Matskevich A.A., McKee H.J., Nichols C.N., Mitchell C.B., Geverd D.A., White M.K., and Strayer M.S. What they are, how they work and why they do what they do? The story of SV40-derived gene therapy vectors and what they have to offer. Curr. Gene. Ther. 5 2 (2005) 151-165
24. Sumida S.M., Truitt D.M., Lemckert A.A., Vogels R., Custers J.H., Addo M.M., Lockman S., Peter T., Peyerl F.W., Kishko M.G., Jackson S.S., Gorgone D.A., Lifton M.A., Essex M., Walker B.D., Goudsmit J., Havenga M.J., and Barouch D.H. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 174 11 (2005) 7179-7185
25. Sweet B.H., and Hilleman M.R. The vacuolating virus, SV40. Proc. Soc. Exp. Biol. Med. 105 (1960) 420-427
26. Tsai B., Gilbert J.M., Stehle T., Lencer W., Benjamin T.L., and Rapoport T.A. Gangliosides are receptors for murine polyoma virus and SV40. EMBO. J. 22 17 (2003) 4346-4355
27. Viscidi R.P., Rollison D.E., Viscidi E., Clayman B., Rubalcaba E., Daniel R., Major E.O., and Shah K.V. Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin. Diagn. Lab. Immunol. 10 2 (2003) 278-285